Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia

Pfeifer, H.; Lange, T.; Wystub, S.; Wassmann, B.; Maier, J.; Binckebanck, A.; Giagounidis, A.; Stelljes, M.; Schmalzing, M.; Duehrsen, U.; Wunderle, L.; Serve, H.; Brueck, P.; Schmidt, A.; Hoelzer, D.; Ottmann, O. G.

dc.contributor.author	Schmalzing, Marc
dc.date.accessioned	2014-03-25T15:35:40Z
dc.date.available	2014-03-25T15:35:40Z
dc.date.issued	2012
dc.identifier.issn	0887-6924
dc.identifier.uri	http://hdl.handle.net/10900/50448
dc.language.iso	en	de_DE
dc.publisher	Nature Publishing Group	de_DE
dc.relation.uri	http://dx.doi.org/10.1038/leu.2012.5	de_DE
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.ddc	610	de_DE
dc.title	Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia	de_DE
dc.type	Article	de_DE
utue.quellen.id	20140226071329_01840	de_DE
utue.publikation.seiten	1475-1481	de_DE
utue.personen.roh	Pfeifer, H.
utue.personen.roh	Lange, T.
utue.personen.roh	Wystub, S.
utue.personen.roh	Wassmann, B.
utue.personen.roh	Maier, J.
utue.personen.roh	Binckebanck, A.
utue.personen.roh	Giagounidis, A.
utue.personen.roh	Stelljes, M.
utue.personen.roh	Schmalzing, M.
utue.personen.roh	Duehrsen, U.
utue.personen.roh	Wunderle, L.
utue.personen.roh	Serve, H.
utue.personen.roh	Brueck, P.
utue.personen.roh	Schmidt, A.
utue.personen.roh	Hoelzer, D.
utue.personen.roh	Ottmann, O. G.
dcterms.isPartOf.ZSTitelID	Leukemia	de_DE
dcterms.isPartOf.ZS-Issue	7	de_DE
dcterms.isPartOf.ZS-Volume	26	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE